Trexquant Investment LP Purchases 25,086 Shares of Core Laboratories Inc. $CLB

Key Points

• Trexquant Investment LP increased its stake in Core Laboratories Inc. by 24.4%, owning 128,037 shares valued at approximately $1.92 million, consolidating its position among institutional investors that collectively hold 97.81% of the stock.
• Core Laboratories recently announced a quarterly dividend of $0.01 per share, contributing to an annualized dividend yield of 0.3%.
• Analysts have given Core Laboratories a consensus rating of "Hold", with recent price target adjustments by Zacks and Stifel Nicolaus, indicating a cautious stance on the company's stock performance.

Trexquant Investment LP boosted its stake in Core Laboratories Inc. (NYSE:CLB - Free Report) by 24.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 128,037 shares of the oil and gas company's stock after purchasing an additional 25,086 shares during the quarter. Trexquant Investment LP owned about 0.27% of Core Laboratories worth $1,919,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CLB. First Trust Advisors LP bought a new stake in Core Laboratories in the fourth quarter valued at about $606,000. Dimensional Fund Advisors LP increased its holdings in Core Laboratories by 3.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 847,983 shares of the oil and gas company's stock valued at $14,678,000 after purchasing an additional 28,393 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Core Laboratories by 843.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock valued at $57,000 after purchasing an additional 2,936 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Core Laboratories by 8.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 36,938 shares of the oil and gas company's stock valued at $640,000 after purchasing an additional 2,784 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Core Laboratories by 15.6% in the fourth quarter. Northern Trust Corp now owns 577,752 shares of the oil and gas company's stock valued at $10,001,000 after purchasing an additional 78,173 shares during the last quarter. Institutional investors own 97.81% of the company's stock.

Core Laboratories Stock Down 3.9%

Shares of NYSE:CLB traded down $0.50 during trading on Wednesday, hitting $12.31. 520,526 shares of the company's stock traded hands, compared to its average volume of 490,033. Core Laboratories Inc. has a 52 week low of $9.72 and a 52 week high of $21.83. The company has a current ratio of 2.27, a quick ratio of 1.70 and a debt-to-equity ratio of 0.47. The company has a market cap of $577.17 million, a price-to-earnings ratio of 19.85, a price-to-earnings-growth ratio of 3.87 and a beta of 1.46. The company has a 50-day moving average price of $11.51 and a 200-day moving average price of $12.31.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.01. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.The business had revenue of $130.16 million for the quarter, compared to analysts' expectations of $129.19 million. During the same quarter in the previous year, the business posted $0.22 EPS. Core Laboratories's revenue for the quarter was down .3% on a year-over-year basis. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. As a group, research analysts forecast that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 25th. Investors of record on Monday, August 4th were issued a dividend of $0.01 per share. The ex-dividend date was Monday, August 4th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.3%. Core Laboratories's dividend payout ratio (DPR) is presently 6.45%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Core Laboratories from a "sell" rating to a "hold" rating in a report on Saturday, July 26th. Zacks Research upgraded Core Laboratories from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Stifel Nicolaus dropped their price objective on Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Finally, Citigroup lowered their price target on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $12.50.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.